Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Sprave, Tetyana [VerfasserIn]   i
 Verma, Vivek [VerfasserIn]   i
 Sterzing, Florian [VerfasserIn]   i
 Bruckner, Thomas [VerfasserIn]   i
 Hees, Katharina [VerfasserIn]   i
 Land, Beate [VerfasserIn]   i
 Jäkel, Oliver [VerfasserIn]   i
 Herfarth, Klaus [VerfasserIn]   i
 Debus, Jürgen [VerfasserIn]   i
 Uhl, Matthias [VerfasserIn]   i
Titel:Cost-effectiveness of carbon ion radiation therapy for skull base chordoma utilizing long-term (10-year) outcome data
Verf.angabe:Tanja Sprave, Vivek Verma, Florian Sterzing, Thomas Bruckner, Katharina Hees, Beate Land, Oliver Jäkel, Klaus Herfarth, Jürgen Debus and Matthias Uhl
E-Jahr:2018
Jahr:August 2018
Umfang:6 S.
Fussnoten:Gesehen am 03.04.2020
Titel Quelle:Enthalten in: Anticancer research
Ort Quelle:Attiki : [Verlag nicht ermittelbar], 2004
Jahr Quelle:2018
Band/Heft Quelle:38(2018), 8, Seite 4853-4858
ISSN Quelle:1791-7530
Abstract:Background/Aim: Carbon ion radiotherapy (CIRT) offers high conformality and ability to dose-escalate skull base chordomas, with promising clinical data. However, it is an imperative measure to economically justify the use of such high-priced new technologies. Herein, we investigated the cost-effectiveness of CIRT compared to photon radiotherapy (PRT) using 10-year outcome data extrapolated to a 34-year time frame. Materials and Methods: Data regarding costs of PRT, as well as 10-year outcomes were obtained from published sources. Corresponding figures for CIRT were acquired from institutional and published sources. Adjustment was made in order to compare both cost figures, including elimination of additional financing and follow-up, so that only direct costs of treatment and the cost of progression were compared between both modalities. The incremental cost-effectiveness ratio (ICER) was calculated as the difference in cost between both modalities divided by the difference in 34-year quality-adjusted life-year (QALY) outcomes. The annual gross domestic product per capita cost-effectiveness threshold definition (as recommended by the WHO) was employed. Results: The total cost of a complete course of CIRT (20-22 fractions) was €31,538.21. After removal of financing and follow-up costs, the adjusted direct cost of CIRT utilized for comparison was €18,957.78. In a previous publication, the cost of PRT was €4,700.00. ICERs were based upon these direct cost figures and the average of reported 10-year progression-free survival (PFS) values with PRT (41.1%) and CIRT (54%), as well as gained PFS years (10.66 years CIRT, 8.58 years PRT). QALYs were 6.65 for photon RT and 8.26 for CIRT, a difference of 1.61 discounted lifetime QALYs for patients treated with CIRT. The overall ICER was €8,855.76/QALY. If the cost of progression/recurrence treated with imatinib were included into the calculation, the total ICER was €170.61/QALY. Conclusion: CIRT is a highly cost-effective option to treat chordoma.
DOI:doi:10.21873/anticanres.12797
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.21873/anticanres.12797
 Volltext: http://ar.iiarjournals.org/content/38/8/4853
 DOI: https://doi.org/10.21873/anticanres.12797
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Carbon ion radiation therapy
 chordoma
 cost-effectiveness
 health care policy
 radiation therapy
K10plus-PPN:1694002616
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68561047   QR-Code
zum Seitenanfang